Cover Image
市場調查報告書

腎細胞癌:KOL的洞察

Renal Cell Carcinoma: KOL Insight

出版商 FirstWord 商品編碼 326363
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
腎細胞癌:KOL的洞察 Renal Cell Carcinoma: KOL Insight
出版日期: 2015年02月01日 內容資訊: 英文
簡介

本報告提供對製藥企業、藥物研發社群來說對商務不可缺少的考察,美國與歐洲的12位KOL的意見、目前治療選擇、新的治療方法、臨床研究的重要角色,及影響癌症專門醫生的處方決策的要素等,主要的臨床醫生的見解彙整,為您概述為以下內容。

主要的要點

  • 依據理解KOL的關心事,制定對臨床醫生通訊有效的策略
  • 依據理解影響RCC領域的重要要素,發現策略性、戰術性動作的主要領域
  • 有高引導強勢產品定位的可能性的臨床實驗的設計
  • 新的治療方法為了獲得市場佔有率,確認治療途徑有降低名次可能性的企業/產品
  • 關於哪個R&D計劃需要投資或中止,實行更基於資訊的決策
  • 為了利用未來競爭企業的弱點,定位初期階段的研究、授權計劃
  • KOL認為預計大幅影響未來治療決策的臨床實驗,並發現其引起的結果
  • 關於處方決策,確定KOL認為最重要的產品特質、患者的特徵
  • 評估變化的競爭情形,確定幫助KOL業務的解決方案
  • 檢討下一代的開發方法,確定機會的領域
目錄
Product Code: 596200288

Will new checkpoint inhibitors revive immunotherapy in RCC?

‘Renal Cell Carcinoma: KOL Insight’ offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights on what leading clinicians think about current treatment options, new therapies, the critical role of clinical research and the factors that influence oncologists' prescribing decisions.

With the expected approval and launch of PD-1 inhibitors such BMS' Opdivo (nivolumab) the options for first- and second-line treatment of RCC are expected to widen over time and impact currently available therapies. While initially these new products will be launched as monotherapies for second-line treatment there is wide anticipation that, in combination, they will ultimately take a commanding role in first-line treatment.

This report gives insights into when and why clinicians will use these new therapies and how it influences their prescribing decisions. In addition, readers will gain insights on which product combinations are most favoured and why, which products are most likely to be affected as the new treatment paradigm takes shape and the strategic lessons for drug discovery and development companies.

Top Takeaways

  • Formulate effective strategies for clinician communication by understanding KOL concerns
  • Find key areas for strategic and tactical action by understanding the important factors affecting the RCC sector
  • Design clinical trials which are more likely to lead to strong product positioning (e.g. more effective comparator, population and endpoint selection)
  • Identify companies/products that are likely to move down the treatment pathway as new therapies gain market share
  • Make more informed decisions about which R&D programmes warrant investment or discontinuation
  • Position your early stage research and licencing plans to exploit future competitor weaknesses
  • Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes (CheckMate-025, METEOR, IMPRINT, ADAPT, SWITCH-II, CROSS-J-RCC, FLIPPER, ASSURE, S-TRAC, PROTECT, and ATLAS)
  • Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
  • Evaluate the changing competitive landscape and identify solutions that aid KOLs in their practice
  • Review next generation development approaches and identify opportunity areas

Gain Answers to Key Questions

  • What clinical advantages do KOLs see in GSK's VEGF TKI Votrient (pazobanib) over Pfizer's Sutent (sunitinib) and how might this play out?
  • What head-to-head clinical trials would help KOLs when making second line treatment decisions?
  • What are the future prospects for mTOR inhibitors such as Novartis'Afinitor (everolimus) and why might KOL's prefer Pfizer's Inlyta and the VEGF TKI options?
  • What cost/benefit consideration should BMS consider for Opdivo in Europe?
  • How might the availability of checkpoint inhibitors give a boost to Roche's Avastin (bevacizumab)?
  • What is the potential of Argos' AGS-003 and Immatics' renal cancer vaccine IMA901 - is their window of opportunity gone?
  • How might the future treatment landscape and late-stage hopefuls influence drug development companies when making their portfolio decisions?

Key Opinion Leaders

North America

  • Michael B. Atkins, MD - Georgetown University School of Medicine, Washington, DC
  • Robert Figlin, MD, FACP Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, CA
  • James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center, NY
  • Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, NY Brian Rini, MD, Case Western Reserve University,OH

Europe

  • Bernard Escudier, MD Institut Gustave Roussy, France Emilio Esteban Hospital Universitario Central de Asturias, Oviedo, Spain
  • Camillo Porta, MD, University of Pavia, Italy Prof
  • Thomas Powles, MBBS, MRCP, MD Barts Cancer Institute, UK
  • Cora Sternberg, MD Institut Gustave Roussy, France
  • 2 anonymous German KOLs

Report Features

  • Insightful drug and development analysis with “real world” opinions of leading US and European KOLs not available elsewhere
  • Detailed and candid views on the future positioning and competitiveness of current and late-stage targeted and immune therapies
  • Essential insights which answer critical business questions in the RCC market for industry marketers, drug discovery/developer companies, clinical researchers and business planners
  • A comprehensive horizon scan for both branded and drug development companies

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, February 2015.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date
Back to Top